Coloplast A-S, a Danish manufacturer of intimate healthcare products, faces market uncertainty due to potential US tariffs, but its solid financial foundation and diversified product portfolio suggest resilience in the face of short-term challenges.

Zimmer Biomet Holdings Inc. has secured approval from Japan’s PMDA for its new hip replacement systems, iTaperloc Complete and iG7 Hip System, marking a significant regulatory milestone and expanding the company’s presence in the orthopedic market.

Abbott Laboratories’ diagnostics division continues to drive growth and stability, despite recent stock price volatility and external challenges, making it an attractive option for income-focused investors.

Merck & Co. has partnered with Danish biotech firm Evaxion A/S to develop and commercialize Evaxion’s vaccine candidate EVX-B3, with the potential to generate significant milestone payments and royalty income as the global vaccine market is projecte…

The 100% tariff on imported branded pharmaceuticals announced by the US President has triggered a decline in stock prices for Japanese pharmaceutical companies, including Chūgai Pharmaceutical Co., Ltd., and poses significant economic and regulator…

McKesson Corporation’s stock has seen a significant surge in recent days, driven by bullish revisions from major investment houses and a consensus view that the company’s prospects are improving, with analysts setting a target price as high as $860.

Humana Inc. has secured a favorable ruling in a Medicare Advantage lawsuit, reinforcing its compliance posture and stability of revenue streams, while also continuing to invest in innovation and precision healthcare solutions.

ResMed Inc., a leading medical device company, has reported sustained growth in its share price and market capitalization, driven by its expertise in sleep-disordered breathing devices and strategic positioning in the expanding smart sleep tracker m…

GSK PLC is navigating market dynamics, reimbursement models, and operational challenges in the healthcare delivery sector, with strategic initiatives such as reviving the Leucovorin therapy and investing in digital transformation expected to drive s…

Shanghai Fosun Pharmaceutical Group Co Ltd is navigating a bearish market trend in the pharmaceutical sector, driven by macroeconomic uncertainties and geopolitical tensions, but its stable stock performance and robust market capitalization suggest …